The Role of Patient Expectancy in Placebo and Nocebo Effects in Antidepressant Trials
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine whether patient expectancy plays a role in observed placebo and nocebo effects in 2 clinical trials. METHOD: Data were reanalyzed from 2 fluoxetine-discontinuation studies conducted from March 1990 to September 1992 and from May 1997 to December 2002. The 673 outpatients included were aged 18-65 years with DSM-III-R major depressive disorder (MDD), responded to 12-week duration open treatment, and were randomized to continued fluoxetine or placebo for an additional year. Participants in 1 of the included studies received a fixed dose of fluoxetine 20 mg daily, while the second study utilized flexible fluoxetine doses up to 60 mg daily. Mixed effects longitudinal models determined whether the possible randomization to placebo at 12 weeks resulted in significant depressive symptom worsening across treatments. Correlations were computed between early symptom change (weeks 1-3 of open treatment) and postrandomization symptom change (weeks 13-16 following randomization). RESULTS: Participants continuing to receive fluoxetine and those switched to placebo had significantly higher mean Hamilton Depression Rating Scale (HDRS) scores immediately postrandomization compared to the final weeks of open treatment (P < .001 for both fluoxetine- and placebo-treated patients). In both studies, early HDRS change was significantly correlated with postrandomization HDRS change for patients receiving fluoxetine (r = -0.46, P < .001) as well as placebo (r = -0.48, P < .001). CONCLUSIONS: The possibility of receiving placebo following 12 weeks of open fluoxetine was associated with significant symptom worsening in 2 large fluoxetine discontinuation studies. Worsening depression scores following randomization were significantly associated with the degree of improvement participants experienced during weeks 1-3 of open treatment. These results suggest that treatment changes influence patients' expectations of improvement, which, in turn, affect their depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Meta-analysis of the placebo response in antidepressant trials.
Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.029 · Cited by 346
Sneed, J. R., Rutherford, B. R., Rindskopf, D., Lane, D. T., Sackeim, H. A., & Roose, S. P. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181256b1d · Cited by 140 · cited 1×
“In Study 1, subjects whose depression met remission criteria after 12 weeks of open-label treatment were randomly assigned to 1 of 4 groups: (1) placebo for 50 weeks, (2) continued fluoxetine for 14 weeks followed by placebo for 36 weeks, (3) continued fluoxetine for 38 weeks followed by placebo for 12 weeks, or (4) c…”
MethodSelf-citationStewart, J. W., Quitkin, F. M., McGrath, P. J., Amsterdam, J., Fava, M., Fawcett, J., Reimherr, F., Rosenbaum, J., Beasley, C., & Roback, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.4.334 · Cited by 113 · cited 1×
“placebo substitution at one of three time points (see Figure 1) (16).”
BackgroundSelf-citationPredictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression
McGrath, P. J., Stewart, J. W., Quitkin, F. M., Chen, Y., Alpert, J. E., Nierenberg, A. A., Fava, M., Cheng, J., & Petkova, E. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1542 · Cited by 111
Self-citationPredictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression
McGrath, P. J., Stewart, J. W., Petkova, E., Quitkin, F. M., Amsterdam, J. D., Fawcett, J., Reimherr, F. W., Rosenbaum, J. F., & Beasley, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0710 · Cited by 65
Self-citation
Cited by
Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety
Rasmussen, K. G. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.002 · Cited by 32
Expectation of nocebo hyperalgesia affects EEG alpha-activity
Albu, S., & Meagher, M. W. (2016) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2016.08.009 · Cited by 29
Changes in typical beliefs in response to complicated grief treatment
Skritskaya, N. A., Mauro, C., Garcia de la Garza, A., Meichsner, F., Lebowitz, B., Reynolds, C. F., Simon, N. M., Zisook, S., & Shear, M. K. (2020) · Depression and Anxiety · doi:10.1002/da.22981 · Cited by 24
Efficacy of antidepressants: bias in randomized clinical trials and related issues
Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1377070 · Cited by 20
Lin, C. ‐., Yang, W. ‐., Chen, C. ‐., & Cai, W. ‐. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13183 · Cited by 8
“In the followup period, relapse was defined as a HAMD17 ≥ 14 (46,47) or rehospitalization for a psychiatric reason (48).”
Method
Metadata
- Authors
- Rutherford, B. R., Wall, M. M., Glass, A., & Stewart, J. W.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2014-06-10
- Volume
- 75
- Issue
- 10
- Pages
- 1040-1046
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2022785617
- Cited by
- 58
- References
- 7
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Patient Expectancy in Placebo and Nocebo Effects in Antidepressant Trials. https://app.cochat.ai/papers/10.4088/jcp.13m08797
- The paper
- Rutherford, B. R., Wall, M. M., Glass, A., & Stewart, J. W. (2014). The Role of Patient Expectancy in Placebo and Nocebo Effects in Antidepressant Trials. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.13m08797
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.